Thus, due to concerns about stimulating myeloid progenitor cells and potentially exacerbating the severity of CRS and ICANS, there has been justifiable hesitancy amongst the cell therapy community to recommend a strategy for using G-CSF to counteract post-CAR T neutropenia [15, 23, 24]. Here, CSF3 is linked to neutropenia.